Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.
about
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients?Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution.Cyclosporine: A Commentary on Brand versus Generic Formulation ExchangeGeneric cyclosporine formulations: more open questions than answers.Altered cytochrome p450 metabolism of calcineurin inhibitors: case report and review of the literature.A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipientsComparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.Comparison of the long-term efficacy and safety of generic Tacrobell with original tacrolimus (Prograf) in kidney transplant recipients.Healthcare costs in renal transplant recipients using branded versus generic ciclosporin.Generic maintenance immunosuppression in solid organ transplant recipients.Generic tacrolimus in solid organ transplantation.Generic immunosuppression in transplantation: current evidence and controversial issues.Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products?Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis.Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.Generic Drugs - Decreasing Costs and Room for Increased Number of Kidney Transplantations.Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.Novel bioequivalence approach for narrow therapeutic index drugs.Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients.Transplant coordinators' perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy.A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.Switchover to generic cyclosporine in stable renal transplant recipients: a single unit experience.Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients.Generic immunosuppression: deciphering the message our patients are receiving.Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients.
P2860
Q33506237-F2757203-7C37-452B-9E1E-D50498D530F0Q34614739-50D63173-D97C-4846-8458-F23703045537Q35147525-1ED5A44D-711D-42D3-BE20-4DC84D1DCE8EQ35486822-FAA98B91-CBEF-44FF-85CC-073264986790Q35607575-FDCC3973-8E2C-4BDC-9B72-5C6B8AE35DC2Q36073209-EA647EDF-4603-431C-A899-97CFA4FFC560Q36188339-C30061FC-F18A-4808-9808-0DF0BA8B8F90Q36319486-0E738F6A-9412-4027-9B95-153D1C8B71E0Q36482172-8C6ED822-9C70-4F15-B710-149D289E21F9Q36941933-5EC6AB6E-83FE-4B48-A787-D976BAEEE9FEQ37588122-099A26D5-1D32-4DAC-840C-8778E54C36C9Q37663649-5A2D6332-F321-4B0D-958B-0686A5F66961Q37949392-77EC19D1-97E3-42A1-B796-7DFC802A619FQ38205921-56D1C04E-EBD1-4353-A5F4-85A112024F18Q38393905-8E342D94-2CEE-42E6-A527-8F8392348143Q38516064-176F42DE-637B-4048-B0DE-A19379A37AF6Q38535040-80E45316-0C50-46B9-8382-BF2C42C15F30Q38703310-7D352B55-3503-49FB-A537-E8BD85560A3CQ38904252-E4D58AAE-85B7-4906-ABDE-299FFF51CEB5Q40706829-7B6CCF2E-9501-4805-93C6-FAA7A265989FQ41452460-43B13544-807E-41E9-B3E9-E8DAEA58DDDBQ41733509-015C1F59-27E5-48EB-A61D-611846826FB2Q41888764-D22106FE-667D-4852-B1C7-2041E5313DF9Q42622920-610FC7B4-A9F9-4070-80DB-37EA02483C01Q45233142-085EF68B-BB40-4DB7-A16A-509B5EE893E2Q47152860-E36715A2-0963-45BA-9740-51F56B2A2EB3Q48119796-B3BE71D8-9482-42CF-837F-CCF4A094F2F5Q50281568-A537C395-C99D-4F0D-889D-A3688551AAEAQ51184201-31FCAB51-8DFC-4380-BA17-4B5891BBD719Q51797706-0F4E89AA-D7BE-4800-A4E2-8DAA52C3479D
P2860
Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Report of the American Society ...... of generic immunosuppressants.
@en
Report of the American Society ...... of generic immunosuppressants.
@nl
type
label
Report of the American Society ...... of generic immunosuppressants.
@en
Report of the American Society ...... of generic immunosuppressants.
@nl
prefLabel
Report of the American Society ...... of generic immunosuppressants.
@en
Report of the American Society ...... of generic immunosuppressants.
@nl
P2093
P2860
P1476
Report of the American Society ...... of generic immunosuppressants.
@en
P2093
Alan Leichtman
Amir Tejani
Harold Helderman
Kathleen Lake
M William Bennett
Peter Hoyer
Rita R Alloway
Ross Isaacs
Steven K Takemoto
P2860
P304
P356
10.1046/J.1600-6143.2003.00212.X
P407
P577
2003-10-01T00:00:00Z